Pharmacovigilance needed for rheumatology patients

Pharmacovigilance needed for rheumatology patients

(HealthDay)—Recommendations have been developed for pharmacovigilance in rheumatology, emphasizing the need for continued monitoring of new drugs, according to a position statement issued by the American College of Rheumatology (ACR).

Researchers from the ACR developed a position statement relating to pharmacovigilance with respect to rheumatology treatment.

According to the statement, the ACR supports robust pharmacovigilance to ensure the safety of all rheumatology medications. In addition, the ACR supports continued development of the Sentinel System by the U.S. Food and Drug Administration; this system relies on information from existing databases to monitor in real time. In order to actively monitor patients for adverse events, the ACR recognizes the role of , with reporting of any serious adverse events through MedWatch. The ACR encourages reporting of full product information, including biosimilar suffix, lot information, and indication for drug use when reporting adverse events related to biologics. Given the current partial reliance on patients for spontaneous reporting of adverse events, pharmacovigilance systems should be readily available and easy for patients to use.

"This statement puts us on record of supporting prompt reporting of new and unexpected side effects to the FDA and advocating for more comprehensive systems to observe safety in practice," Donald R. Miller, Pharm.D., member of the ACR's Committee on Rheumatologic Care, said in a statement.

More information: ACR Position Statement

Copyright © 2018 HealthDay. All rights reserved.

Citation: Pharmacovigilance needed for rheumatology patients (2018, September 13) retrieved 20 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA warns against long-term azithromycin use for some


Feedback to editors